May 22, 2024

The Global Advanced Glycation End Products Market is Trending by Continuous Innovation in Treatment Modalities

The advanced glycation end products (AGEs) market encompasses various products that are used for the measurement and inhibition of AGEs formation and breaking of established AGE-protein crosslinks in conditions such as diabetes, kidney diseases, and neurodegenerative disorders. AGEs are protein and lipid adducts generated by nonenzymatic reactions between sugars and free amino groups in proteins, lipids, or nucleic acids. Continuous research and development activities are focused on developing AGE inhibitors and breakers to prevent tissue damage caused by the accumulation of AGEs.

The Global Advanced Glycation End Products Market is estimated to be valued at US$ 3,469.95 Mn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030.

Key Takeaways

Key players operating in the advanced glycation end products are Daval International Ltd, EKF Diagnostics Holdings PLC, Asahi Kasei pharmaceuticals Corp, AMS Biotechnology (Europe) Limited, and Diagnostic Products Corporation.

Growing prevalence of diabetes and chronic kidney disease and rising research in developing AGE inhibitors is fueling the demand for AGEs detection and inhibition in the market. According to the International Diabetes Federation, the global prevalence of diabetes among adults aged 20-79 years is projected to rise to 643 million people by 2030.

Major players are focused on expanding their presence globally to tap the demand for AGE measurement and inhibition products especially in emerging markets of Asia Pacific and Latin America. In June 2019, AMS Biotechnology opened a new production facility in Zurich, Switzerland to strengthen its position in European region.

Market Key Trends

Focus on developing novel AGE inhibitors is one of the major trends witnessed in the advanced glycation end products market. Researchers are evaluating the efficacy of various compounds such as pyridoxamine, aspirin, benfotiamine, aminoguanidine, and metformin as AGE inhibitors. In June 2019, a team of engineers from the MIT announced that they are developing a method of converting liquid nanoemulsions into solid gels to improve the delivery of AGE inhibitors to tissues.

Porter’s Analysis

Threat of new entrants: New players need high investments for R&D and clinical trials to gain regulatory approvals, limiting threats.

Bargaining power of buyers: There exists large customer base with increasing awareness, giving buyers high bargaining power.

Bargaining power of suppliers: Suppliers of raw materials have some bargaining power due to specialized expertise required.

Threat of new substitutes: Substitutes are available but limited by efficacy and regulatory compliances.

Competitive rivalry: Large players continue R&D to enhance portfolios and gain market share intensifying competition.

The advanced glycation end products market in North America is currently the largest, valued at over US$ 1,289.12 Mn in 2023 owing to rising diabetes prevalence and obesity rates along with favorable reimbursement policies for therapies. Asia Pacific is projected to be the fastest growing regional market expanding at a CAGR of 14.3% during the forecast period on account of increasing healthcare expenditure and large patient population affected with diabetes and chronic kidney diseases in countries like India and China.

The advanced glycation end products market in Europe was valued at US$ 942.31 Mn in 2024 and is expected to witness robust growth. This can be attributed to growing research initiatives to develop innovative therapeutics by pharmaceutical companies and availability of funds for clinical research from European Commission. Japan also represents a significant opportunity due to aging population susceptible to diabetes and focus on diabetes management.

*Note:

  1. Source: Coherent Market Insights, Public sources, Desk research
  2. We have leveraged AI tools to mine information and compile it